Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03232164 · ClinicalTrials.gov registry record · Early Phase 1

PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

A Early Phase 1 study, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Early Phase 1
Development phase
126
Enrollment target

NCT03232164 is a Early Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 126 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03232164, a Early Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Early Phase 1
Development phase
126 participants
Enrollment target

Study Summary

The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence. Development of such a biomarker may be useful to differentiate indolent from aggressive prostate cancer phenotypes allowing for selection of an appropriate risk adaptive therapy.

Interventions

  • DRUG 18F-DCFPyL PET

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2017-02-02
Est. Completion 2024-11-01
Phase Early Phase 1

Sponsor

University of Wisconsin, Madison

1,039 total trials

What the Registry Record Tells You About NCT03232164

The ClinicalTrials.gov registry entry for NCT03232164 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which 18F-DCFPyL PET is the first listed.

NCT03232164 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03232164 about?

NCT03232164 is a clinical study titled "PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer". The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence. Development of such a biomarker may be useful to differentiate indolent from aggressive prostate cancer phenotypes allowing for selection of an app...

What is the current status of trial NCT03232164?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 126 participants. The study started on 2017-02-02. Estimated completion is 2024-11-01.

What interventions are being tested in trial NCT03232164?

The interventions under investigation include: 18F-DCFPyL PET (DRUG).

Who is sponsoring clinical trial NCT03232164?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.